Details of the Drug

General Information of Drug (ID: DMU9MYJ)

Drug Name

Oxandrolone

Synonyms

Anavar; Lonavar; Ossandrolone; Oxandrin; Oxandrolona; Oxandrolonum; Protivar; Provitar; Vasorome; Ossandrolone [DCIT]; SC 11585; Anavar (TN); Oxandrin (TN); Oxandrolona [INN-Spanish]; Oxandrolonum [INN-Latin]; SC-11585; Oxandrin, Anavar, Oxandrolone; Oxandrolone (JAN/USP/INN); Oxandrolone [USAN:INN:BAN:JAN]; Dodecahydro-3-hydroxy-6-(hydroxy-methyl)-3,3a,6-trimethyl-1H-benz(e)indene-7-acetic acid delta-lactone; (1S,3aS,3bR,5aS,9aS,9bS,11aS)-1-hydroxy-1,9a,11a-trimethyl-2,3,3a,3b,4,5,5a,6,9,9b,10,11-dodecahydroindeno[4,5-h]isochromen-7-one; (4aS,4bS,6aS,7S,9aS,9bR,11aS)-7-hydroxy-4a,6a,7-trimethyltetradecahydroindeno[4,5-h]isochromen-2(1H)-one; 17-beta-hydroxy-17-methyl-2-oxa-androstan-3-one; 17-beta-hydroxy-17-methyl-2-oxa-androstan-3-one (9CI); 17beta-Hydroxy-17-methyl-2-oxa-5alpha-androstan-3-one; 17beta-Hydroxy-17alpha-methyl-2-oxa-5alpha-androstan-3-one; 2-Oxa-5alpha-androstan-3-one, 17beta-hydroxy-17-methyl-(8CI); 2-Oxaandrostan-3-one, 17-hydroxy-17-methyl-, (5-alpha,17-beta)-(9CI)

Indication

Disease Entry	ICD 11	Status	REF
Alcoholic hepatitis	DB94.1	Approved	[1]

Affected Organisms

Humans and other mammals

ATC Code

A14AA08: Oxandrolone

A14AA: Androstan derivatives

A14A: ANABOLIC STEROIDS

A14: ANABOLIC AGENTS FOR SYSTEMIC USE

A: ALIMENTARY TRACT AND METABOLISM

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

306.4

Logarithm of the Partition Coefficient (xlogp)

3.7

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Bioavailability: 97% of drug becomes completely available to its intended biological destination(s) [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 0.55 hours [4]
Metabolism: The drug is metabolized via renal []

Chemical Identifiers

Formula: C19H30O3
IUPAC Name: (1S,3aS,3bR,5aS,9aS,9bS,11aS)-1-hydroxy-1,9a,11a-trimethyl-2,3,3a,3b,4,5,5a,6,9,9b,10,11-dodecahydroindeno[4,5-h]isochromen-7-one
Canonical SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C
InChI: InChI=1S/C19H30O3/c1-17-11-22-16(20)10-12(17)4-5-13-14(17)6-8-18(2)15(13)7-9-19(18,3)21/h12-15,21H,4-11H2,1-3H3/t12-,13+,14-,15-,17-,18-,19-/m0/s1
InChIKey: QSLJIVKCVHQPLV-PEMPUTJUSA-N

Cross-matching ID

PubChem CID: 5878
ChEBI ID: CHEMBL1200436
CAS Number: 53-39-4
UNII: 7H6TM3CT4L
DrugBank ID: DB00621
TTD ID: D0U3GL
ACDINA ID: D00497

Drug Pharmacogenomic Perturbation (DPP)^NEW

Click to Jump to the Detailed DPP Information of This Drug

Drug ADMET Endpoint Profile (DAE)^NEW

Click to Jump to the Detailed DAE Information of This Drug

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Androgen receptor (AR)	TTS64P2	ANDR_HUMAN	Agonist	[5]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Sex hormone-binding globulin (SHBG)	OTPWU5IW	SHBG_HUMAN	Gene/Protein Processing	[6]

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Alcoholic hepatitis

ICD Disease Classification

DB94.1

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Androgen receptor (AR)	DTT	AR	2.13E-01	-0.07	-0.11

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Oxandrolone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Oxandrolone and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[7]
Repaglinide	DM5SXUV	Moderate	Increased risk of hypoglycemia by the combination of Oxandrolone and Repaglinide.	Acute diabete complication [5A2Y]	[8]
Tolazamide	DMIHRNA	Moderate	Increased risk of hypoglycemia by the combination of Oxandrolone and Tolazamide.	Acute diabete complication [5A2Y]	[8]
Nateglinide	DMLK2QH	Moderate	Increased risk of hypoglycemia by the combination of Oxandrolone and Nateglinide.	Acute diabete complication [5A2Y]	[8]
Insulin-glulisine	DMQI0FU	Moderate	Increased risk of hypoglycemia by the combination of Oxandrolone and Insulin-glulisine.	Acute diabete complication [5A2Y]	[8]
Insulin-aspart	DMX7V28	Moderate	Increased risk of hypoglycemia by the combination of Oxandrolone and Insulin-aspart.	Acute diabete complication [5A2Y]	[9]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Oxandrolone and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[10]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Oxandrolone and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[11]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Oxandrolone and Cannabidiol.	Epileptic encephalopathy [8A62]	[12]
Efavirenz	DMC0GSJ	Moderate	Increased risk of hepatotoxicity by the combination of Oxandrolone and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Fluvastatin	DM4MDJY	Moderate	Decreased metabolism of Oxandrolone caused by Fluvastatin mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[7]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Oxandrolone and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[14]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Oxandrolone and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[15]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Oxandrolone and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[16]
Pirfenidone	DM6VZFQ	Moderate	Decreased metabolism of Oxandrolone caused by Pirfenidone mediated inhibition of CYP450 enzyme.	Idiopathic interstitial pneumonitis [CB03]	[12]
Lesinurad	DMUR64T	Moderate	Decreased metabolism of Oxandrolone caused by Lesinurad mediated inhibition of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[17]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Oxandrolone and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[18]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Oxandrolone and Idelalisib.	Mature B-cell leukaemia [2A82]	[19]
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of Oxandrolone and Clofarabine.	Mature B-cell lymphoma [2A85]	[20]
Carfilzomib	DM48K0X	Major	Additive thrombogenic effects by the combination of Oxandrolone and Carfilzomib.	Multiple myeloma [2A83]	[7]
Siponimod	DM2R86O	Major	Decreased metabolism of Oxandrolone caused by Siponimod mediated inhibition of CYP450 enzyme.	Multiple sclerosis [8A40]	[7]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Oxandrolone caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[21]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Oxandrolone and Leflunomide.	Rheumatoid arthritis [FA20]	[15]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Oxandrolone and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[12]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Oxandrolone and Naltrexone.	Substance abuse [6C40]	[22]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Oxandrolone and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[8]
Chlorpropamide	DMPHZQE	Moderate	Increased risk of hypoglycemia by the combination of Oxandrolone and Chlorpropamide.	Type 2 diabetes mellitus [5A11]	[8]
Insulin-detemir	DMOA4VW	Moderate	Increased risk of hypoglycemia by the combination of Oxandrolone and Insulin-detemir.	Type-1/2 diabete [5A10-5A11]	[8]
Insulin degludec	DMPL395	Moderate	Increased risk of hypoglycemia by the combination of Oxandrolone and Insulin degludec.	Type-1/2 diabete [5A10-5A11]	[8]


⏷ Show the Full List of 29 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Oxandrolone 10 mg tablet	10 mg	Oral Tablet	Oral
Oxandrolone 2.5 mg tablet	2.5 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7092).
2	BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
3	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	The effect of oxandrolone treatment on human osteoblastic cells. J Burns Wounds. 2007 Mar 7;6:e4.
6	Low sex hormone-binding globulin and testosterone levels in association with erectile dysfunction among human immunodeficiency virus-infected men receiving testosterone and oxandrolone. J Sex Med. 2008 Jan;5(1):241-7. doi: 10.1111/j.1743-6109.2007.00634.x. Epub 2007 Oct 24.
7	Cerner Multum, Inc. "Australian Product Information.".
8	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
9	Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
10	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
11	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
12	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
13	Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
14	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
15	Canadian Pharmacists Association.
16	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
17	Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
18	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
19	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
20	Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
21	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
22	Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.